MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Full Archive

The full archive of mesothelioma-related journal articles. All articles belong to this category.

Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018)

Lung Cancer 2019 January [Link] Wu L, Dell’Anno I, Lapidot M, Sekido Y, Chan ML, Kohno M, Serre-Beinier V, Felley-Bosco E, de Perrot M Abstract Here we summarize the most recent update of mesothelioma research in basic science presented at the 14th iMig2018 international conference. The symposium of basic science track mainly focused on the drivers of mesothelioma initiation […]

Comments Off on Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018)

Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.

Proceedings of the National Academy of Sciences of the United States of America 2019 January 18 [Link] Villanova T, Gesmundo I, Audrito V, Vitale N, Silvagno F, Musuraca C, Righi L, Libener R, Riganti C, Bironzo P, Deaglio S, Papotti M, Cai R, Sha W, Ghigo E, Schally AV, Granata R Abstract Malignant pleural mesothelioma […]

Comments Off on Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.

Prognostic Factors of Survival in Patients with Malignant Pleural Mesothelioma; an analysis of the National Cancer Data Base.

Carcinogenesis; 2019 January 10 [Link] van Gerwen M, Alpert N, Wolf A, Ohri N, Lewis E, Rosenzweig KE, Flores R, Taioli E Abstract Malignant pleural mesothelioma is a rare disease with a very poor prognosis. Previous studies have indicated that women experience longer survival compared to men. We analyzed 16,267 eligible patients (21.3% females) in […]

Comments Off on Prognostic Factors of Survival in Patients with Malignant Pleural Mesothelioma; an analysis of the National Cancer Data Base.

ADAM10 mediates malignant pleural mesothelioma invasiveness.

Oncogene 2019 January 16 [Link] Sépult C, Bellefroid M, Rocks N, Donati K, Gérard C, Gilles C, Ludwig A, Duysinx B, Noël A, Cataldo D Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited therapeutic options and treatment efficiency. Even if the latency period between asbestos exposure, the main risk factor, and mesothelioma […]

Comments Off on ADAM10 mediates malignant pleural mesothelioma invasiveness.

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo.

Experimental and Therapeutic Medicine 2019 January [Link] Ye L, Lou Y, Lu L, Fan X Abstract Non-small cell lung cancer (NSCLC) and mesothelioma are renowned for being diagnosed at a late stage and poor prognosis. Although surgery, chemotherapy, and radiotherapy have yielded successful outcomes, the improvement on the survival rate of NSCLC and mesothelioma have been less marked. […]

Comments Off on Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo.

Dosimetric Correlates of Pulmonary Toxicity in Patients with Malignant Pleural Mesothelioma Receiving Radiation Therapy to the Intact Lungs.

Practical Radiation Oncology 2019 January 14 [Link] Thompson MR1, Dumane VA1, Lazarev SA1, Zia Y2, Rosenzweig KE3 INTRODUCTION: We aimed to determine dose-volume constraints that correlate with severe (grade ≥3) radiation pneumonitis (RP) in patients diagnosed with malignant pleural mesothelioma (MPM), treated using volumetric modulated arc therapy (VMAT). METHODS: Data from 40 patients with MPM who underwent pleurectomy decortication (P/D) and […]

Comments Off on Dosimetric Correlates of Pulmonary Toxicity in Patients with Malignant Pleural Mesothelioma Receiving Radiation Therapy to the Intact Lungs.

Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma.

Lung Cancer 2019 January [Link] Kumar N, Alrifai D, Kolluri KK, Sage EK, Ishii Y, Guppy N, Borg E, Falzon M, Nankivell M, Nicholson AG, Janes SM Abstract Introduction BRCA1 associated protein-1 (BAP1) is a key tumor driver in mesothelioma and a potential biomarker predicting response to several targeted therapies in clinical testing. Whether it also modulates response to cytotoxic chemotherapy is undetermined. This study used […]

Comments Off on Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma.

Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.

Lung Cancer 2019 January [Link] Chapel DB, Churg A, Santoni-Rugiu , Tsujimura T4, Hiroshima K5, Husain AN Abstract The pathologist plays a central role in the diagnosis and management of malignant mesothelioma, including definitive tissue-based diagnosis in conjunction with clinical and radiographic data; diverse ancillary studies of diagnostic, prognostic, and predictive importance; and research efforts to better define the pathobiology of […]

Comments Off on Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.

Well-Differentiated Papillary Mesothelioma of the Peritoneum: A Retrospective Study from the RENAPE Observational Registry.

Annals of Surgical Oncology 2019 January 11 [Link] Vogin G1, Hettal L, Vignaud JM, Dartigues P, Goere D, Ferron G, Heyd B, Bereder JM, Tuech JJ, Glehen O,  de Chaisemartin C, Lherm Y, Villeneuve L, Kepenekian V, Marchal F BACKGROUND: Well-differentiated papillary mesothelioma of the peritoneum (WDPMP) is a rare entity. Questions regarding management are still being debated as no more than 50 cases have been reported in the literature. OBJECTIVE: […]

Comments Off on Well-Differentiated Papillary Mesothelioma of the Peritoneum: A Retrospective Study from the RENAPE Observational Registry.

Heparanase inhibitors restrain mesothelioma.

Oncotarget 2018 December 7 [Link] Lapidot M1, Barash U1, Vlodavsky I1, Pass H2. Abstract Malignant mesothelioma is a highly aggressive form of cancer with poor prognosis due to lack of markers for early diagnosis and resistance to conventional therapies. Heparanase, the sole heparan sulfate (HS) degrading endoglycosidase, regulates multiple biological activities that enhance tumor growth, metastasis, angiogenesis, and inflammation. Heparanase accomplishes this […]

Comments Off on Heparanase inhibitors restrain mesothelioma.